The objective of this article (and the corresponding symposium) was to assume an "opposition" stance and argue against the presumed usefulness of long-acting injections (LAI) for the treatment of patients with schizophrenia. Here, LAI demonstrated limited patient applicability and were found to be used infrequently in Japan, with insufficient evidence to their efficacy suggesting that LAI would be more appropriate playing a supplementary role in the pharmacotherapy guidelines for schizophrenia. Additionally, any potential benefits of LAI have yet to be fully realized in Japan due to the fact that 80% of patients treated with LAI for schizophrenia are also prescribed antipsychotics orally, and a hesitance towards LAI by psychiatrists is likely to be reflected in their limited usage nationwide, an attitude which may present an ethical problem in terms of just principles.
 <Author's abstract>